Catalyst Pharmaceuticals, Inc.
CPRX
$24.49
$0.381.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.97% | 23.49% | 32.17% | 43.42% | 60.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.97% | 23.49% | 32.17% | 43.42% | 60.38% |
| Cost of Revenue | -39.89% | -43.84% | -48.23% | 137.54% | 151.23% |
| Gross Profit | 68.71% | 62.09% | 87.90% | 18.82% | 33.60% |
| SG&A Expenses | 17.75% | 32.93% | 66.02% | 90.17% | 114.47% |
| Depreciation & Amortization | 5.65% | 14.78% | 54.00% | 124.82% | 363.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.93% | -4.75% | 5.15% | 111.61% | 144.15% |
| Operating Income | 195.38% | 124.77% | 129.15% | -37.87% | -34.77% |
| Income Before Tax | 199.54% | 128.82% | 133.62% | -35.40% | -30.73% |
| Income Tax Expenses | 188.66% | 126.72% | 144.96% | -13.24% | -15.88% |
| Earnings from Continuing Operations | 203.07% | 129.50% | 130.18% | -41.02% | -34.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 203.07% | 129.50% | 130.18% | -41.02% | -34.49% |
| EBIT | 195.38% | 124.77% | 129.15% | -37.87% | -34.77% |
| EBITDA | 136.03% | 94.58% | 110.85% | -20.77% | -10.83% |
| EPS Basic | 178.13% | 104.98% | 110.06% | -47.03% | -37.90% |
| Normalized Basic EPS | 171.58% | 106.29% | 109.32% | -41.78% | -36.16% |
| EPS Diluted | 190.43% | 114.48% | 122.52% | -47.07% | -39.35% |
| Normalized Diluted EPS | 183.57% | 115.84% | 120.96% | -42.25% | -37.32% |
| Average Basic Shares Outstanding | 9.65% | 11.46% | 8.90% | 6.80% | 4.83% |
| Average Diluted Shares Outstanding | 10.04% | 11.55% | 8.81% | 3.36% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |